Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-04-22 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思2024年“提质增效重回报”行动方案
Investor Presentation Classification · 90% confidence The document is titled as a "2024年度‘提质增效重回报’专项行动方案" which translates to a "2024 Special Action Plan for Quality Improvement, Efficiency Enhancement, and Return to Shareholders." It outlines the company's strategic plans for operational improvements, talent development, marketing expansion, investor returns including dividend and share repurchase plans, governance improvements, and investor relations activities. The document includes detailed descriptions of the company's plans for shareholder returns, including dividends and share buybacks, but it is not a formal dividend notice or earnings release. It is a strategic action plan document aimed at investors and stakeholders, focusing on operational and financial improvement initiatives rather than reporting actual financial results or earnings. The document length is 3648 characters, which is relatively short and does not contain detailed financial statements or comprehensive financial data. It is not an announcement of a report publication but a standalone plan document. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation of company strategy, financial plans, and market positioning for investors.
2024-04-22 Chinese
安杰思关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (auditor) for the company for the fiscal year 2024. It details the auditor's qualifications, independence, audit fees, and the approval process by the board and shareholders. It does not contain any financial statements or audit results but is a formal notice about the auditor appointment process. The document length is short (2396 characters) and it is clearly an announcement rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR) category, which includes standalone audit reports and related announcements about audit firms, excluding full annual reports. The confidence is high given the clear content and context. FY 2024
2024-04-22 Chinese
安杰思2023年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the year 2023, detailing the audit firm's background, audit procedures, and their fulfillment of duties. It references auditing standards, the audit of the 2023 financial report, and internal control effectiveness. The content focuses on the audit firm's role and performance rather than presenting the full annual financial report itself. The document length is 2762 characters, which is relatively short and consistent with a standalone audit report or evaluation rather than a full Annual Report (10-K). There is no indication that this is an announcement or a certification letter. Therefore, the document fits best under the category of Audit Report / Information (AR).
2024-04-22 Chinese
安杰思关于2023年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2023 annual profit distribution plan of Hangzhou Anjiesi Medical Technology Co., Ltd. It details the proposed cash dividend and stock dividend per 10 shares, the basis for distribution, and the approval process including board and supervisory committee meetings. It also mentions that the plan is subject to approval at the 2023 annual general meeting. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related procedural information. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2024-04-22 Chinese
安杰思董事会审计委员会对2023年度会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report from the Board Audit Committee regarding the supervision of the accounting firm for the fiscal year 2023. It details the audit firm's qualifications, the audit committee's evaluation and oversight activities, and the audit process for the 2023 annual audit. The content focuses on the audit committee's supervisory role and the audit firm's performance rather than presenting full financial statements or a comprehensive annual report. The document length is 3619 characters, which is relatively short and focused on audit supervision rather than the full annual report. This matches the description of an Audit Report / Information filing, which includes standalone audit reports and results of internal or regulatory audits, excluding full annual reports. Therefore, the appropriate classification is AR (Audit Report / Information).
2024-04-22 Chinese
安杰思2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Annual Special Report on the Deposit and Actual Use of Raised Funds" by Hangzhou Anjiesi Medical Technology Co., Ltd. It details the amount of funds raised through an IPO, the timing of fund receipt, the use and balance of these funds, management of the funds, and compliance with regulatory requirements. It includes detailed financial figures about the raised funds, their allocation, and usage status, as well as auditor and sponsor opinions on the fund usage. The document is a specialized report focusing on the management and use of capital raised by the company, which aligns with the definition of a Capital/Financing Update (CAP) filing. It is not a full annual report, audit report, or earnings release, but a specific report on fundraising and capital usage. The document length (8152 characters) and content confirm it is the report itself, not just an announcement of a report publication.
2024-04-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.